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Objective: Important differences between men and women with asthma have been demon-
strated, with women describing more symptoms and worse asthma-related quality of life
(QOL) despite having similar or better pulmonary function. While current guidelines focus
heavily on assessing asthma control, they lack information about whether sex-specific ap-
proaches to asthma assessment should be considered. We sought to determine if sex differ-
ences in asthma control or symptom profiles exist in the well-characterized population of
participants in the American Lung Association Asthma Clinical Research Centers (ALA-ACRC)
trials.
Methods: We reviewed baseline data from four trials published by the ALA-ACRC to evaluate
individual item responses to three standardized asthma questionnaires: the Juniper Asthma
Control Questionnaire (ACQ), the multi-attribute Asthma Symptom Utility Index (ASUI), and Ju-
niper Mini Asthma Quality of Life Questionnaire (mini-AQLQ).
Results: In the poorly-controlled population, women reported similar overall asthma control
(mean ACQ 1.9 vs. 1.8; p Z 0.54), but were more likely to report specific symptoms such as
nocturnal awakenings, activity limitations, and shortness of breath on individual item re-
sponses. Women reported worse asthma-related QOL on the mini-AQLQ (mean 4.5 vs. 4.9;
p < 0.001) and more asthma-related symptoms with a lower mean score on the ASUI (0.73
vs. 0.77; p  0.0001) and were more likely to report feeling bothered by particular symptoms
such as coughing, or environmental triggers.
Conclusions: In participants with poorly-controlled asthma, women had outwardly similar
asthma control, but had unique symptom profiles on detailed item analyses which were
evident on evaluation of three standardized asthma questionnaires.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Population studies reveal sex-related differences in asthma
that change with age. In children and early adolescents,
asthma is more common in boys [1e3]. After puberty,
asthma becomes more common and more severe in women.
Women with asthma describe more symptoms and worse
quality of life (QOL) than men despite having comparable or
better pulmonary function [4e7]. Similarly, women with
asthma report greater healthcare utilization [4e6] andmore
frequent use of short-acting beta-agonists (SABA) [5e7] than
men. While the reasons for these observed sex-related
differences in asthma morbidity and disease expression
have not been fully explained, differences in perception of
airflow obstruction [5,8], increased bronchial hyper-
responsiveness in women as a result of increased suscepti-
bility to tobacco smoke [9,10], and hormonal influences
[11e13] have all been proposed as potential hypotheses.
Sex-specific treatment approaches to asthma care have
been developed, and have shown benefit to women when
compared to standard nonspecific approaches [14,15].
Despite these findings, current asthma guidelines [16] lackinformation about whether sex-specific approaches to
asthma assessment should be considered. Using detailed
evaluation of previously validated questionnaires, we sought
to determine if sex differences in asthma control or symp-
tom profiles exist in the population of participants in the
American Lung Association Asthma Clinical Research Centers
(ALA-ACRC) trials, supporting the need for sex-specific ap-
proaches to asthma assessment. Some of the results have
been reported previously in the form of an abstract [17]. By
examining commonly utilized questionnaires in this manner,
the ALA-ACRC data offer a unique approach to the evalua-
tion of the potential influence of sex on the assessment of
asthmamorbidity and quality of life, and take advantage of a
large well-characterized population of participants.Methods
Study design and participants
The ALA-ACRC is a multi-center network of 20 centers
dedicated to improving asthma care through clinical
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collected at enrollment from four published trials [18e21]
by the ALA-ACRC to evaluate item responses of men and
women to three standardized asthma questionnaires. A
detailed description of the design and inclusion/exclusion
criteria for each study is provided elsewhere [18e21].
The analyses included one trial of participants with well-
controlled asthma (the Leukotriene or Corticosteroid or
CorticosteroideSalmeterol [LOCCS] trial [20]) and three
trials of participants with poorly-controlled asthma
(Effectiveness of Low Dose Theophylline as Add-On Therapy
In Treatment of Asthma [LODO] [18], Study of Acid Reflux
and Asthma [SARA] [19], and the Trial of Asthma Patient
Education [TAPE] [21]) as determined by criteria for study
enrollment. Eligibility criteria for each trial are included in
the online supplement (Appendix). Participants 17 years of
age or older were included.
Demographic and clinical assessments
Data were obtained from the baseline assessments of par-
ticipants prior to the initiation of study interventions. De-
mographic and clinical data including targeted co-morbid
conditions were evaluated.
Sex-specific item analysis of standard asthma
questionnaires
Asthma control was assessed with the seven-question Ju-
niper Asthma Control Questionnaire (ACQ) [22] (range, 0e6,
with lower scores indicating less severe asthma and 0.5
units considered a minimal clinically important difference
[MID] [23], with scores 1.5 defined as poor control).
Asthma symptoms were evaluated with the multi-attribute
Asthma Symptom Utility Index (ASUI) [24] (range, 0e1, with
higher scores indicating less severe asthma and 0.09
considered an MID [25]). Asthma-related QOL was assessed
with the Juniper Mini Asthma Quality of Life Questionnaire
(mini-AQLQ) [26] (range, 1e7, with higher scores indicating
better QOL and 0.5 considered the MID) [19]. We examined
overall scores and individual item responses for sex-related
differences in controlled versus poorly-controlled
asthmatics.
Statistical analysis
Data from participants enrolled in more than one trial were
included only from the latest trial in which the participant
enrolled. Analyses were stratified by control status
(controlled vs. poorly-controlled) as defined by the criteria
required for trial eligibility [18e21]. For continuous vari-
ables, analyses were adjusted for trial, and as specified,
other characteristics using linear regression models; non-
adjusted analyses were based on Wilcoxon Rank Sum
Tests. For categorical variables, unadjusted analyses were
performed using Chi-square and Fisher’s Exact Tests; ana-
lyses including covariate adjustments were performed with
logistic regression models. For analysis of specific ques-
tionnaire items, responses were categorized by presence or
absence of the symptom. Analyses were performed in SAS
version 9.2 (SAS Institute).Results
Demographic and clinical characteristics
We reviewed baseline data of 1612 participants (287 well-
controlled asthmatics from LOCCS and 1325 poorly-
controlled asthmatics from LODO [n Z 412], TAPE
[n Z 514], and SARA [n Z 399] respectively). Ages ranged
from 17 to 85, and the majority (70%) was women. Partic-
ipants were stratified by asthma control and further
compared by sex using baseline demographic and clinical
characteristics (Tables 1 and 1BA).
Among poorly-controlled participants, men were diag-
nosed with asthma at an earlier age (16.4  16.9 vs.
19.4  16.6 years; p < 0.001), and had a lower BMI
(28.7  6.1 vs. 31.4  8.7 kg/m2; p < 0.001). Men reported
more frequent use of SABA and had a lower mean % pre-
dicted post-bronchodilator forced expiratory volume in one
second (FEV1) (85.2  15.5 vs. 89.1  15.0; p < 0.01) but no
difference in bronchial hyper-responsiveness as defined by
methacholine challenge. Women were more likely to report
concomitant gastroesophageal reflux disease (GERD) (26%
vs. 20%; p Z 0.03), eczema (17% vs. 12%; p Z 0.04), and
sinusitis (44% vs. 29%; p < 0.001), and were more likely to
report allergy-exacerbated asthma symptoms (83% vs. 77%;
pZ 0.01) or treatment for an exacerbation in the last year
(46% vs. 36%; p < 0.001).
For controlled subjects, there were few differences
noted between men and women. Men had a lower mean %
predicted pre-bronchodilator FEV1 (89.4  9.4 vs.
92.4  10.7; p < 0.01), and women were more likely to
report concomitant sinusitis (36% vs. 18%; p Z 0.001).
Item responses to asthma questionnaires
In the poorly-controlled population, women reported
similar overall asthma control (mean ACQ 1.9 vs. 1.8;
p Z 0.54), but were more likely to report frequent
nocturnal awakenings, more limitations in activities, and
more shortness of breath related to their asthma (Table 2)
than men on individual item responses. Women also re-
ported worse asthma-related QOL on the mini-AQLQ (mean
4.5 vs. 4.9; p < 0.001 respectively) (Table 3) where they
were more likely to report feeling bothered by symptoms
such as coughing (72% vs. 60%; p < 0.001), or environmental
triggers for asthma such as dust (85% vs. 73%; p < 0.001),
cigarette smoke (81% vs. 68%; p < 0.001), and weather and
air pollution (66% vs. 47%; p < 0.0001), and were more
likely to report limitations with activities. They were also
more likely to report difficulty sleeping related to their
asthma (57% vs. 48%; p Z 0.01). After adjusting for the
increased frequency of co-morbid conditions in women,
differences in reported shortness of breath noted on the
ACQ and reports of interference with sleep or social activ-
ities on the mini-AQLQ were no longer significant. However,
the rest of the item responses evaluated were unaffected.
Among participants with poorly-controlled asthma,
women reported more asthma-related symptoms with a
lower mean score on the ASUI (0.73 vs. 0.77; p  0.0001)
(Table 4). Compared to men, women were more likely to
report feeling bothered by coughing (80% vs. 67%;
Table 1A Demographic and baseline clinical characteristics of well-controlled asthma population.
Women
N Z 181 (63%)
Men
N Z 106 (37%)
p-value
Demographic and clinical characteristics
N Mean (SD) N Mean (SD)
Age in years 181 35.7 (13.2) 106 33.6 (11.2) 0.36
Race N % N %
White 126 70 71 67 0.17
Black 44 24 22 21
Other 11 6 13 12
Hispanic
Yes 14 8 10 9 0.62
No 167 92 96 91
Smoking status
Current 12 7 7 7 0.69
Former 40 22 19 18
Never 129 71 80 75
N Mean (SD) N Mean (SD)
BMI (kg/m2) 181 28.7 (7.6) 106 27.7 (5.7) 0.85
Other self-reported conditions N % N %
GERD 46 25 22 21 0.37
Eczema 27 15 12 11 0.39
Chronic sinusitis 65 36 19 18 0.001
Food allergies 49 27 21 20 0.17
Allergic rhinitis 110 61 62 58 0.70
Asthma characteristics
Asthma exacerbation in prior year 60 33 27 25 0.17
Allergies reported trigger for asthma 149 82 90 85 0.57
N Mean (SD) N Mean (SD)
Age of asthma diagnosis in years 177 17.0 (15.0) 104 15.1 (15.1) 0.18
Pulmonary function
Pre-bronchodilator FEV1 % predicted 181 92.4 (10.7) 106 89.4 (9.4) <0.01
Post-bronchodilator FEV1 % predicted 180 97.6 (11.4) 103 95.9 (11.2) 0.13
% change FEV1 180 5.6 (5.9) 103 7.4 (6.8) 0.06
Pre-bronchodilator FVC% predicted 181 100.3 (12.5) 106 99.8 (12.8) 0.81
Post-bronchodilator FVC% predicted 180 101.6 (14.2) 103 100.2 (13.7) 0.62
% change FVC 180 1.3 (9.1) 103 0.6 (5.6) 0.47
PC20 methacholine (mg/dL) 35 3.7 (3.6) 23 3.7 (4.2) 0.82
Chronic asthma medications N % N %
Inhaled SABA 120 66 71 67 0.91
ICS 38 21 27 25 0.38
LABA 13 7 4 4 0.31
LABA/ICS 68 38 28 26 0.05
Leukotriene modifiers 30 17 10 9 0.09
Inhaled anticholinergics 4 2 0 0 0.30
Cromolyn sodium or nedocromil 5 3 1 1 0.42
Oral beta-agonists 1 1 0 0 >0.99
Methylxanthines 1 1 0 0 >0.99
Oral corticosteroids 0 0 1 1 0.37
Herbal or natural supplements 32 18 9 8 0.03
SD Z standard deviation; BMI Z body mass index; GERD Z gastroesophageal reflux disease; FEV1 Z forced expiratory volume in one
second; FVC Z forced vital capacity; PC20 Z provocative concentration of methacholine; SABA Z short-acting beta-agonist;
ICS Z inhaled corticosteroid; LABA Z long-acting beta-agonist.
1494 J.W. McCallister et al.p < 0.001), were more likely to describe symptoms such as
coughing, wheezing, and shortness of breath as moderate
or severe (p < 0.001, pZ 0.03, and p < 0.01 respectively),
and were more likely to report nocturnal asthma symptoms(62% vs. 50%; p<0.001). After adjusting for the increased
frequency of co-morbid conditions in women, severity of
wheezing and shortness of breath were no longer significant
but the other item responses were not affected.
Table 1B Demographic and baseline clinical characteristics of poorly-controlled asthma population.
Women
N Z 953 (72%)
Men
N Z 372 (28%)
p-value*
Demographic and clinical characteristics
N Mean (SD) N Mean (SD)
Age in years 953 40.9 (13.8) 372 39.6 (14.2) 0.09
Race N % N %
White 563 59 217 58 0.62
Black 316 33 120 32
Other 74 8 35 9
Hispanic
Yes 81 9 29 8 0.68
No 872 92 343 92
Smoking status
Current 51 5 20 5 0.18
Former 336 35 151 41
Never 566 59 201 54
N Mean (SD) N Mean (SD)
BMI (kg/m2) 951 31.4 (8.7) 371 28.7 (6.1) <0.0001
Other self-reported conditions N % N %
GERD 248 26 76 20 0.03
Eczema 111 17 31 12 0.04
Chronic sinusitis 422 44 107 29 <0.0001
Food allergies 138 21 54 20 0.73
Allergic rhinitis 626 66 230 62 0.19
Asthma characteristics
Asthma exacerbation in prior year 440 46 134 36 <0.001
Allergies reported trigger for asthma 791 83 286 77 0.01
N Mean (SD) N Mean (SD)
Age of asthma diagnosis in years 933 19.1 (16.6) 365 16.4 (16.9) <0.001
Pulmonary function
Pre-bronchodilator FEV1 % predicted 953 82.5 (15.4) 371 78.0 (16.3) <0.0001
Post-bronchodilator FEV1 % predicted 948 89.1 (15.0) 370 85.2 (15.5) <0.0001
% change FEV1 948 9.0 (11.2) 370 10.4 (14.3) <0.01
Pre-bronchodilator FVC% predicted 952 89.9 (14.5) 371 90.5 (15.9) 0.35
Post-bronchodilator FVC% predicted 948 93.5 (14.7) 370 95.0 (4.5) 0.03
% change FVC 948 4.5 (9.5) 370 5.9 (11.7) 0.01
PC20 methacholine (mg/dL) 128 3.3 (4.3) 47 3.3 (4.1) 0.82
Chronic asthma medications N % N %
Inhaled SABA 779 82 323 87 0.03
ICS 265 28 112 30 0.40
LABA 90 9 36 10 0.90
LABA/ICS 550 58 201 54 0.24
Leukotriene modifiers 109 11 32 9 0.14
Inhaled anticholinergics 26 3 7 2 0.37
Cromolyn sodium or nedocromil 5 1 4 1 0.28
Oral beta-agonists 4 <1 1 <1 >0.99
Methylxanthines 3 <1 3 1 0.36
Oral corticosteroids 17 2 2 1 0.12
Herbal or natural supplements 86 13 28 11 0.25
SD Z standard deviation; BMI Z body mass index; GERD Z gastroesophageal reflux disease; FEV1 Z forced expiratory volume in one
second; FVC Z forced vital capacity; PC20 Z provocative concentration of methacholine; SABA Z short-acting beta-agonist;
ICS Z inhaled corticosteroid; LABA Z long-acting beta-agonist.
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few differences between men and women. The mean score
on the ACQ was similar for men and women (0.7 vs. 0.7;
p Z 0.53) and there were no significant differences notedon sex-specific analyses of the individual item responses
(data not shown). Men and women also reported similar
asthma-related QOL on the mini-AQLQ with mean scores of
5.9 and 5.7 (pZ 0.09) respectively. For the individual item
Table 2 Juniper Asthma Control Questionnaire (ACQ) responses for poorly-controlled subjects. Individual item responses were
analyzed by sex of respondent, and describe the preceding seven days. ACQ7 Z seven-question asthma control questionnaire;
SDZ standard deviation; CIZ 95% confidence interval; FEV1Z forced expiratory volume in one second; pZ p-value adjusted
for trial, age, race and body mass index; p* Z p-value adjusted for trial, age, race, body mass index, gastroesophageal reflux
disease, eczema, sinusitis, and rhinitis.
Women
N Z 952 (72%)
Men
N Z 372 (28%)
p p*
Mean SD 95% CI Mean SD 95% CI
ACQ7 1.9 0.8 1.9, 2.0 1.8 0.8 1.8, 1.9 0.54 0.36
Woken by asthma past week? 1.5 1.3 1.4, 1.6 1.3 1.2 1.1, 1.4 <0.01 0.02
How bad were symptoms? 1.9 1.1 1.9, 2.0 1.8 1.1 1.7, 1.9 0.08 0.11
How limited in activities? 1.8 1.2 1.7, 1.9 1.5 1.2 1.4, 1.6 0.001 0.02
How much shortness of breath did you experience? 2.5 1.1 2.4, 2.5 2.3 1.1 2.1, 2.4 0.03 0.07
How much time did you wheeze? 2.0 1.3 1.9, 2.1 1.9 1.2 1.8, 2.0 0.89 0.68
How many puffs of short-acting bronchodilator each day? 1.5 1.0 1.5, 1.6 1.5 1.1 1.4, 1.6 0.91 0.75
Table 3 Mini Asthma Quality of Life Questionnaire (AQLQ) in poorly-controlled subjects. Individual item responses were
analyzed by sex of respondent, and describe the preceding two weeks. p Z p-value adjusted for age, race, and body mass
index; p* Z p-value adjusted for trial, age, race, body mass index, gastroesophageal reflux disease, eczema, sinusitis, and
rhinitis; SD Z standard deviation.
Women Men p p*
Mean (SD) Median Mean (SD) Median
AQLQ Score 4.5 (1.2) 4.5 4.9 (1.1) 5.0 <0.0001 0.001
Women % Men %
Feel short of breath as a result of your
asthma?
No time 148 16 76 20 0.08 0.20
Any time 804 84 296 80
Feel bothered by or have to avoid dust in
the environment?
No time 139 15 100 27 <0.0001 <0.0001
Any time 813 85 272 73
Feel frustrated as a result of your asthma? No time 340 36 147 40 0.44 0.94
Any time 612 64 225 60
Feel bothered by coughing? No time 264 28 149 40 <0.001 0.01
Any time 688 72 223 60
Feel afraid of not having your asthma
medication?
No time 431 45 151 41 0.09 0.04
Any time 521 55 221 59
Experience a feeling of chest tightness or
chest heaviness?
No time 245 26 113 30 0.11 0.86
Any time 707 74 259 70
Feel bothered by or have to avoid cigarette
smoke in the environment?
No time 180 19 118 32 <0.0001 <0.001
Any time 772 81 254 68
Have difficulty getting a good night’s sleep
as a result of your asthma?
No time 406 43 193 52 0.01 0.10
Any time 546 57 179 48
Feel concerned about having asthma? No time 343 36 140 38 0.98 0.58
Any time 609 64 232 62
Experience a wheeze in your chest? No time 276 29 119 32 0.62 0.68
Any time 676 71 253 68
Feel bothered by or have to avoid going
outside because of weather or air pollution?
No time 327 34 198 53 <0.0001 <0.001
Any time 625 66 174 47
Limitations with strenuous activities? No time 235 25 139 37 <0.001 <0.01
Any time 717 75 233 63
Limitations with moderate activities? No time 400 42 228 61 <0.0001 <0.001
Any time 552 58 144 39
Limitations with social activities? No time 644 68 282 76 0.04 0.06
Any time 308 32 90 24
Limitations with work-related activities? No time 631 66 270 73 0.17 0.46
Any time 321 34 102 27
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Table 4 Asthma symptom utility index (ASUI) in poorly-controlled subjects. Individual item responses were analyzed by sex of
respondent, and describe the preceding two weeks. p Z p-value adjusted for trial, age, race, and body mass index; p* Z p-
value adjusted for trial, age, race, body mass index, gastroesophageal reflux disease, eczema, sinusitis, and rhinitis;
SD Z standard deviation.
Women
(n Z 953, 72%)
Men
(n Z 372, 28%)
p p*
Mean (SD) Median Mean (SD) Median
ASUI score 0.73 (0.16) 0.75 0.77 (0.14) 0.80 <0.0001 <0.01
Women % Men %
How many days were you bothered
by coughing?
Not at all 189 20 121 33 <0.0001 <0.001
Others 764 80 251 67
On average, how severe was your
cough?
Mild 452 59 181 72 <0.001 0.01
Moderate 277 36 61 24
Severe 35 5 9 4
How many days were you bothered
by wheezing?
Not at all 210 22 72 19 0.11 0.33
Others 743 78 300 81
On average, how severe was your
wheezing?
Mild 497 67 226 75 0.03 0.08
Moderate 230 31 70 23
Severe 16 2 4 1
How many days were you bothered by
shortness of breath?
Not at all 79 8 38 10 0.47 0.83
Others 874 92 334 90
On average, how severe was your
shortness of breath?
Mild 522 60 235 70 <0.01 0.12
Moderate 326 37 94 28
Severe 26 3 5 2
How many days were you awakened
at night by your asthma?
Not at all 364 38 186 50 <0.001 0.001
Others 589 62 186 50
On average, how much of a problem
was being awakened at night?
Mild 368 62 127 68 0.12 0.10
Moderate 199 34 54 29
Severe 22 4 5 3
How many days were you bothered by
side effects of asthma medications?
Not at all 756 79 318 85 <0.01 <0.01
Others 197 21 54 15
On average, how severe were the
side effects?
Mild 140 71 36 67 0.78 0.56
Moderate 53 27 18 33
Severe 4 2 0 0
Sex differences in asthma symptom profiles 1497responses, women were more likely to report feeling
bothered by cigarette smoke (69% vs. 49%; p < 0.01) or by
weather and air pollution (36% vs. 21%; pZ 0.02), but there
were otherwise no differences noted (data not shown). For
the ASUI, women reported more overall asthma-related
symptoms with a lower mean score of 0.87 vs. 0.90
(p Z 0.04), and were more likely to report being bothered
by cough (46% vs. 33%; pZ 0.04). Otherwise, there were no
significant differences noted. When adjusted for the pres-
ence of co-morbid conditions, there was no effect on the
differences noted for individual item responses noted on
the AQLQ, but there was no longer a statistical difference
noted between men and women who reported coughing in
the preceding two weeks on the ASUI (p Z 0.06).
Discussion
The ALA-ACRC trials provide data on a group of well-
characterized participants with asthma. The current
analysis focuses on sex-related differences in a subgroup
of participants 17 years of age or older enrolled in four
clinical trials. Results showed that in participants with
poorly-controlled asthma, women had outwardly similarasthma control as measured by the mean score on the
seven-question ACQ, but reported more asthma symptoms
and poorer asthma-related QOL, compared to men despite
having better pulmonary function and similar baseline
asthma medications. Interestingly, men reported more
frequent use of SABA despite reporting less frequent
asthma symptoms, suggesting that men may tend to
under-report their asthma symptoms. Although the mean
differences noted between poorly-controlled men and
women on the ASUI and mini-AQLQ were statistically sig-
nificant, they did not achieve the MID which has previously
been described as important [19,25], initially suggesting
that there were no important sex differences in asthma
symptoms or QOL. However, our data suggest there are
sex-related differences for a subset of asthma symptoms
that may be disguised when looking at overall scores. The
subset of symptoms for which there were notable signifi-
cant differences included nocturnal awakenings and limi-
tation in activities, which are likely to influence QOL and
resultant responses on QOL assessments. These sex-
related differences in asthma symptom expression
became much less evident in the setting of well-controlled
disease.
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tween the sexes in asthma symptoms and control [4e7,27].
Survey data has shown that women report worse asthma
control and greater healthcare utilization [6] despite noting
more frequent use of controller medications [27]. In addi-
tion, women frequently report worse asthma-related
quality of life despite demonstrating better pulmonary
function [4,5,7,28]. In a cluster analysis of the Severe
Asthma Research Program, Moore et al. described five
distinct asthma phenotypes [29] including a group of pri-
marily women with frequent co-morbid conditions and
symptoms out of proportion to documented airflow
obstruction. This phenotype bears a striking resemblance to
the adult women with poorly-controlled asthma in the
current study.
The data presented here extend the current under-
standing of the differences between adult men and women
with asthma; we present an objectively characterized
group of asthmatics, using a combination of standardized
asthma control questionnaires and pulmonary function
testing to hone in on those factors that may be contributing
to poor asthma control in women, and how they differ from
men. Accordingly, this study is the first to examine sex-
specific responses to standardized questionnaires in a
detailed fashion.
Few have attempted to assess sex-specific differences in
asthma symptom profiles and asthma control on standard
questionnaires. Lee et al. [4] assessed sex-related differ-
ences in severe asthmatics, and noted that when women
reported more control problems on the Asthma Therapy
Assessment Questionnaire (ATAQ) [30] they were more
likely to report nocturnal awakenings and missed activities
despite having better pulmonary function. In a survey of a
managed care population, sex differences were noted in
item responses to the mini-AQLQ, with women noting more
asthma symptoms and specific triggers such as cigarette
smoke, weather, and air pollution [6]. Wijnhoven et al. [7]
noted some sex-specific differences in item responses to
the Quality of Life in Respiratory Illness Questionnaire [31]
in a survey of patients with asthma in some age groups, but
not others.
There are several possible explanations for the sex-
specific differences noted in item responses to the ques-
tionnaires in this study. Women with poorly-controlled
asthma reported more GERD and sinusitis, and were more
likely to associate their asthma symptoms with allergies.
These findings are similar to other studies [4,6] where
women with asthma were more likely to report allergic co-
morbidities or sinusitis, and seemed to be more susceptible
to environmental triggers [27] than men. These conditions
could potentially worsen asthma control, or perhaps more
importantly, result in symptoms which mimic asthma and
potentially influence the response on the questionnaires
evaluated here. In the adjusted analysis, the presence of
these factors altered the significance of a few, but not
most, responses, suggesting that some differences may be
related to their presence, while others may be inherent
differences between men and women. Others have sug-
gested that women may have increased bronchial hyper-
responsiveness as a result of an increased susceptibility to
tobacco smoke [9,10], perhaps contributing to this
increased sensitivity to environmental triggers. However,we did not find a sex-related difference in the provocative
concentration of methacholine (PC20) at baseline in our
patients.
Another possible explanation may be an increased
awareness of dyspnea or an increased tendency to manifest
symptoms in women. It has been shown that inspiratory
muscle strength is significantly greater in men than women
with asthma, and is inversely related to dyspnea [8]. Simi-
larly, in healthy female nonsmokers, women demonstrate a
lower cough reflex threshold associated with a greater urge
to cough and a greater sense of dyspnea when compared to
males [32]. Finally, it is possible that factors such as pre-
menstrual worsening of asthma [33e35] or increased anxi-
ety and depression in women with asthma [36] which were
not easily accounted for in this analysis could explain some
of the sex-related differences we identified.
These findings support the fact that men and women
experience asthma differently. As asthma care providers,
this information can be used to begin developing sex-
specific evaluation and treatment plans which target
these differences. There are two major clinical implica-
tions of our results. Men may have poorer perception of
their disease severity than women, as expressed by poorer
pulmonary function and less impairment on standardized
asthma questionnaires. This would imply that men need to
be carefully screened with testing including lung function
to accurately assess impairment. Women may have more
severe disease in terms of asthma-related symptoms and
impact on QOL despite having more preserved pulmonary
function, and co-morbidities such as sinusitis may be
particularly important in women. One size does not fit all
for asthma assessment, and patients may benefit from sex-
specific interventions. Clark et al. [14,15] have shown that
female-specific asthma management improves asthma-
related QOL and results in decreased use of rescue in-
halers when compared to usual care.
A few limitations to our study must be noted. First, the
cross-sectional study design provided only a single evalua-
tion of each participant’s asthma control. Despite the use
of standardized questionnaires, many findings were based
on self-report and are subject to recall bias. Finally, the
original ALA-ACRC studies were not designed to specifically
address the question at hand.Conclusion
Our findings suggest that using the overall score alone on
currently available asthma questionnaires may not detect
sex-specific differences in asthma symptoms, allowing
asthma care providers to miss potential opportunities to
develop targeted asthma care plans which may improve
asthma control for their patients. In addition to utilizing
these tools as a global assessment of asthma control,
practitioners should be attentive to the potential differ-
ences in symptoms which men and women may experience
and their potential impact on asthma-related QOL and
functional limitation. While future research explores the
need for more focused evaluation tools, providers should
examine individual item responses with attention to
particular sex-specific patterns which may signal areas of
sub-optimal control.
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